
Our pick · Oct 2026
Embody
from $49/mo
Compounded semaglutide · 12-month plan · $588 up front · checked Oct 27
- LegitScript certified
Our pick is a commercial choice. We may earn a commission when you join.
Does Arkansas Medicaid cover GLP-1s for weight loss?
If you are an adult and weight loss is your only reason, Arkansas Medicaid does not cover a GLP-1.
If one of the uses below applies to you, your prescriber can ask Arkansas Medicaid to cover that drug. Read the rule and its criteria.
Which drugs Arkansas Medicaid covers, and for what:
We checked 2 official documents on October 12, 2026. This is information, not medical advice or a benefit decision.
4 programs that serve Arkansas publish a complete monthly price, from $49 at Embody to $297 at Direct Meds GLP-1.

Our pick · Oct 2026
from $49/mo
Compounded semaglutide · 12-month plan · $588 up front · checked Oct 27
Our pick is a commercial choice. We may earn a commission when you join.
Some programs are affiliate partners, and we may earn a commission if you join through our link. Payment never moves a row. How we rank

Compounded semaglutide · 12-mo prepay
$588 up front
Advertised program price, not an insurance copay.
Good: 7.6/10 · Compounded
Checked Oct 16, 2026; a rating claim didn't match Trustpilot.
$588 upfront for 12 months of semaglutide. Yearly-plan sale ends December 1; confirm renewal. Paid terms are normally non-refundable; provider-determined medical disqualification allows a refund for the unused term, less services already provided.
The October 27–December 1, 2026 sale offers semaglutide at $49/month equivalent ($588 prepaid for twelve months) and tirzepatide at $99/month equivalent ($1,188 prepaid). One-month plans remain $79 and $129. The published terms say the rate stays fixed on the selected plan. Confirm the renewal amount and date before paying; these sale rates are not month-to-month bills.
We checked this price on Oct 27, 2026.
Full review and sources
12-mo prepay
$1,188 up front
Advertised program price, not an insurance copay.
Fair: 7.3/10 · Compounded
Checked Jul 18, 2026; few independent reviews yet.
$1,188 paid once for the 12-month semaglutide plan; does not renew. Separate monthly subscription: $99 first, then $165. Confirm how four-week vial supplies cover the billing term.
12-month semaglutide one-time plan: $1,188 paid up front, with no renewal. Separate monthly Subscribe and Save is $99 for the first month, then $165. Product pages describe four-week vials; confirm supply coverage across the selected billing term.
We checked this price on Sep 3, 2026.
Full review and sources$99/mo equivalent at Trimi Health
12-mo prepay
$1,188 up front
Advertised program price, not an insurance copay.
Good: 7.6/10 · Compounded
Checked Jul 2, 2026.
$1,188 upfront for 12 months; applicable taxes may add to the bill 12-month prepay: $1,188 upfront ($99 monthly equivalent); does not auto-renew. The separate month-to-month semaglutide plan is $175
We checked this price on Oct 20, 2026.
Full review and sourcesfrom$297/mo at Direct Meds GLP-1

Confirm the full bill
Advertised program price, not an insurance copay.
Good: 7.5/10 · Compounded
Checked Oct 16, 2026.
Confirm the current prescribed treatment and full bill with the provider.
We checked this price on Sep 3, 2026.
Full review and sources3 more programs serve Arkansas without one complete monthly price: Collective, Maximus and Wellorithm. Compare their terms in the price index.
We left out 26 programs whose service-area list has a caveat for Arkansas or is incomplete, so confirm your address at intake.
A program that serves Arkansas still decides whether to prescribe. Before enrolling, confirm whether it accepts your Medicaid plan and whether your prescribed treatment is covered. The advertised cash prices are not insurance copays. Most listed programs sell compounded semaglutide or tirzepatide, which is not FDA-approved. Check a compounded provider before you pay.
Here is our summary of the Arkansas Medicaid rules we checked, with their criteria and limits.
Arkansas Medicaid's October 2026 criteria exclude GLP-1 prescriptions solely for weight loss, but provide separate authorization routes for other indications. Wegovy injections and tablets have a cardiovascular-risk pathway for people with established cardiovascular disease and overweight or obesity. Wegovy's MASH pathway is injection-only and requires noncirrhotic disease with F2-F3 liver fibrosis plus other criteria. For people with type 2 diabetes and MASH, the criteria require a GLP-1 indicated for diabetes. Zepbound has an obstructive sleep apnea pathway with obesity, an additional qualifying condition and documented treatment requirements. Ask your prescriber to check the exact product and indication in the full criteria before applying. For Zepbound, that includes the six-month weight-management and positive-airway-pressure requirements. These pathways are not automatic approvals or general weight-loss coverage. Individual managed-care processing and all pediatric exceptions have not been established here.
A drug on the preferred list is not covered for every use, so check the rule for yours. A weight-loss exclusion leaves diabetes and other medical requests to their own rules.
We checked Arkansas Medicaid criteria, revised October 1, 2026: Wegovy, pp. 541-544 on October 12, 2026.
We checked Arkansas Medicaid criteria: Zepbound for sleep apnea, pp. 604-605 on October 12, 2026.
Call your Medicaid plan, Medicare drug plan or private insurer with these questions, and keep the reference number for each call.
Before you pay cash, confirm:
An “insurance accepted” badge does not tell you your benefit, so ask your plan how its review works.
Your prescriber sends Arkansas Medicaid a request with the records that show you meet the rule for your drug and diagnosis, and Arkansas Medicaid decides.
What Arkansas Medicaid's own criteria ask for, from the documents we read:
What your prescriber usually sends:
Your prescriber works from these Arkansas Medicaid documents:
Your prescriber's office files the request; you cannot file it yourself. If Arkansas Medicaid says no, ask for the reason in writing, because the notice tells you how to ask for a review and by when.
Medicare's GLP-1 Bridge follows federal rules in every state, so Arkansas Medicaid's policy does not decide your Medicare benefit.
We checked CMS's Bridge guidance for Part D plans on September 26, 2026.
Two free official services can help you, and we earn no commission from either.
Arkansas Medicaid's October 2026 criteria exclude GLP-1 prescriptions solely for weight loss, but provide separate authorization routes for other indications.
Wegovy injections and tablets have a cardiovascular-risk pathway for people with established cardiovascular disease and overweight or obesity. Wegovy's MASH pathway is injection-only and requires noncirrhotic disease with F2-F3 liver fibrosis plus other criteria. For people with type 2 diabetes and MASH, the criteria require a GLP-1 indicated for diabetes. Zepbound has an obstructive sleep apnea pathway with obesity, an additional qualifying condition and documented treatment requirements. Ask your prescriber to check the exact product and indication in the full criteria before applying. For Zepbound, that includes the six-month weight-management and positive-airway-pressure requirements. These pathways are not automatic approvals or general weight-loss coverage. Individual managed-care processing and all pediatric exceptions have not been established here. Before you pay, confirm your exact drug, your diagnosis, any age rules and your plan's authorization steps.
Yes.
Medicare's GLP-1 Bridge follows federal eligibility rules in every state, not Arkansas Medicaid's policy. Your ordinary Part D coverage depends on your prescription and your drug plan, and the Bridge runs its own eligibility and authorization review.
Yes, from 7 online programs that publish a service area including Arkansas.
At intake, confirm your address, the exact medication and any pharmacy limits, because a state listing does not guarantee you a prescription or a delivery date.
Among programs that serve Arkansas, the lowest complete monthly price we found is $49 at Embody.
Across the 10 compounded programs we track nationally, the median advertised recurring price is $124/mo, from $49 to $299. That national figure is not a measured Arkansas average, insurance copay or quote for your dose.
Affiliate partners we feature. We may earn a commission.
Check the medication, commitment and total price for your selected plan.
Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. Published scores have different evidence limits and do not establish better care. See the program comparison and scoring limitations.